Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Actinium Pharmaceuticals Inc (NY: ATNM ) 8.000 +0.680 (+9.29%) Official Closing Price Updated: 8:00 PM EDT, Jul 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 809,008 Open 7.450 Bid (Size) 7.860 (1) Ask (Size) 8.150 (10) Prev. Close 7.320 Today's Range 7.421 - 8.640 52wk Range 4.000 - 10.24 Shares Outstanding 21,331,314 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 3 Under-$10 Biotech Stocks That Could Make You Rich July 11, 2024 Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. Via InvestorPlace 3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns July 02, 2024 These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline. Via InvestorPlace Performance YTD +50.38% +50.38% 1 Month +6.95% +6.95% 3 Month +14.94% +14.94% 6 Month +55.64% +55.64% 1 Year +11.89% +11.89% More News Read More Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions June 18, 2024 Via Newsfile Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress June 18, 2024 Via AB Newswire Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase June 17, 2024 Via FinancialNewsMedia Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase June 17, 2024 From FN Media Group LLC Via GlobeNewswire Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies June 17, 2024 Via FinancialNewsMedia Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML) June 17, 2024 Via Newsfile Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress June 17, 2024 Via FinancialNewsMedia Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress June 17, 2024 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 June 10, 2024 Via InvestorPlace Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar June 07, 2024 Via InvestorPlace 3 Cheap Biotech Stocks to Buy Now: May 2024 May 14, 2024 Via InvestorPlace Exposures Product Safety Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside May 09, 2024 Via AB Newswire Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions May 08, 2024 Via AB Newswire ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024 April 29, 2024 Via InvestorPlace Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market April 25, 2024 Via Investor's Business Daily Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty April 19, 2024 Via AB Newswire Topics Economy Exposures Interest Rates Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM) April 18, 2024 Via AB Newswire Topics Economy Exposures Interest Rates Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest April 17, 2024 Via AB Newswire Biotech on a Budget: 7 Stocks Under $10 With Huge Potential April 15, 2024 Via InvestorPlace Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey March 28, 2024 Via AB Newswire Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial March 27, 2024 Via AB Newswire Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave March 26, 2024 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum March 22, 2024 Via AB Newswire Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.